1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1992
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptoms
1991
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal responseLong-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology GroupSuperiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaCo-trimoxazole prophylaxisComplete response rateDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1989
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Longo D, Glatstein E, Duffey P, Ihde D, Hubbard S, Fisher R, Jaffe E, Gilliom M, Young R, DeVita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. Journal Of Clinical Oncology 1989, 7: 1295-302. PMID: 2788716, DOI: 10.1200/jco.1989.7.9.1295.Peer-Reviewed Original ResearchConceptsInvolved field radiation therapyRadiation therapyComplete remissionAggressive lymphomaCoronary artery bypass surgeryInvolved-field radiation therapyEarly hematogenous disseminationLocalized aggressive lymphomaTreatment-related deathsClinical stage IHigh-dose methotrexateArtery bypass surgeryCombination chemotherapy programsCycles of treatmentMedian followAggressive histologyBypass surgeryLeucovorin rescueChemotherapy programCombination chemotherapyHospital admissionLocal therapyHematogenous disseminationEffective treatmentLymphoma histology
1988
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone A, Longo D, DeVita V, Ihde D, Duffey P, Jaffe E, Solomon D, Hubbard S, Young R. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal Of Clinical Oncology 1988, 6: 1832-7. PMID: 3199167, DOI: 10.1200/jco.1988.6.12.1832.Peer-Reviewed Original ResearchConceptsResidual abdominal massesClinical complete remissionAbdominal massAggressive lymphomaNational Cancer InstituteStable residual massComplete remissionCombination chemotherapyPathologic evaluationFull-dose combination chemotherapyResidual massSubsequent tumor necrosisViable lymphoma cellsEvidence of diseaseMonths of chemotherapyInitial tumor sizeRestaging laparotomyBulky diseaseNegative laparotomyDisseminated diseaseIntraabdominal diseaseMost patientsSurgical explorationResidual tumorResidual diseaseThe role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1986
Twenty years of MOPP therapy for Hodgkin's disease.
Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V. Twenty years of MOPP therapy for Hodgkin's disease. Journal Of Clinical Oncology 1986, 4: 1295-306. PMID: 3528400, DOI: 10.1200/jco.1986.4.9.1295.Peer-Reviewed Original ResearchConceptsEnd of treatmentHodgkin's diseaseComplete responseDisease patientsLymphocyte-depleted typeHodgkin's disease patientsHigher CR rateResults of treatmentMOPP therapyB symptomsIntercurrent illnessComplete remissionLonger remissionsCR rateHodgkin's lymphomaLonger survivalBiopsy specimensPatientsHigh dosesDiseaseRemissionLymphomaMore cyclesTreatmentLarge cells
1985
Current Management of Hodgkin’s Disease
Behrens B, Young R, DeVita V. Current Management of Hodgkin’s Disease. Drugs 1985, 30: 355-367. PMID: 3905335, DOI: 10.2165/00003495-198530040-00004.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's diseaseDurable complete remissionAcute side effectsCombination chemotherapy programsLong-term complicationsPrognosis of patientsImproved treatment approachesProbable cureInduction therapySalvage therapyMost patientsTerm complicationsChemotherapy programSuch patientsStandard radiotherapySpecific therapySide effectsTreatment approachesPatientsCurrent managementCurrent trialDiseaseTherapyRemissionRenal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.
Geffen D, Fisher R, Longo D, Young R, DeVita V. Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. Journal Of Clinical Oncology 1985, 3: 646-53. PMID: 3998781, DOI: 10.1200/jco.1985.3.5.646.Peer-Reviewed Original ResearchConceptsNormal renal functionSerum creatinine levelsRenal involvementDiffuse aggressive lymphomasRenal functionCombination chemotherapyCreatinine levelsAggressive lymphomaElevated serum creatinine levelInitial local controlRecurrent renal diseaseEvidence of diseaseSite of recurrenceResults of treatmentComplete remissionDisseminated diseaseRenal diseaseSystemic diseaseHodgkin's lymphomaComplete resolutionRadiographic criteriaPatientsLocal controlLymphomaChemotherapyProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.Peer-Reviewed Original ResearchConceptsComplete remissionCombination chemotherapyAdvanced stageComplete response rateLong-term survivalMOPP combination chemotherapyC-MOPPComplete respondersNew regimenHodgkin's lymphomaBurkitt's lymphomaDiffuse lymphomaResponse rateFatal diseaseLymphomaPatientsDeath rateNCI studyHigh gradeRemissionChemotherapyDiseaseLarge cellsMyelosuppressionRegimenTreatment of diffuse large cell non-Hodgkin’s lymphomas
Fisher R, Devita V, Longo D, Ihde D, Young R. Treatment of diffuse large cell non-Hodgkin’s lymphomas. Developments In Oncology 1985, 465-469. DOI: 10.1007/978-1-4613-2607-6_49.Peer-Reviewed Original ResearchLong-term disease-free survivalDisease-free survivalAdvanced stageAdvanced diffuse histiocytic lymphomaDiffuse mixed lymphomaDiffuse histiocytic lymphomaDiffuse large cellDiffuse aggressive lymphomasLarge cell lymphomaComplete remissionComplete respondersCombination chemotherapyMixed lymphomaAggressive lymphomaHodgkin's lymphomaHistiocytic lymphomaTherapeutic resultsCell lymphomaBurkitt's lymphomaLymphomaFatal diseaseTreatment programPatientsSurvivalLarge cells
1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDurationProlonged initial remission in patients with nodular mixed lymphoma.
Longo D, Young R, Hubbard S, Wesley M, Fisher R, Jaffe E, Berard C, DeVita V. Prolonged initial remission in patients with nodular mixed lymphoma. Annals Of Internal Medicine 1984, 100: 651-6. PMID: 6370065, DOI: 10.7326/0003-4819-100-5-651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideFemaleHumansLeucovorinLymphoma, FollicularMaleMechlorethamineMethotrexateMiddle AgedNeoplasm StagingPrednisoneProcarbazinePrognosisRetrospective StudiesTime FactorsVincristineConceptsNodular mixed lymphomaComplete response rateMixed lymphomaComplete respondersInitial remissionMedian survivalResponse rateOverall complete response ratePrimary treatment regimensBone marrow involvementLactate dehydrogenase levelsNational Cancer InstituteAverage remissionB symptomsComplete remissionFirst remissionMarrow involvementShorter survivalTreatment regimensDehydrogenase levelsRemissionPatientsStage ICancer InstituteLymphoma
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1981
The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture
Devita V. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture. Cancer 1981, 47: 1-13. PMID: 6970069, DOI: 10.1002/1097-0142(19810101)47:1<1::aid-cncr2820470102>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseLong-term adverse consequencesPresence of symptomsNational Cancer InstituteMOPP programComplete remissionNodular sclerosisHistologic subtypeImmunosuppressive drugsNational mortalityEffective chemotherapyDrug treatmentCancer InstituteChemotherapyDiseaseCarcinogenic effectsAdverse effectsYoung populationMOPPAdverse consequencesImportant negative influenceRemissionSclerosisPatientsPrognosis
1979
Chemotherapy of Hodgkin's disease
Young R, DeVita V. Chemotherapy of Hodgkin's disease. Clinics In Haematology 1979, 8: 625-644. PMID: 91466, DOI: 10.1016/s0308-2261(79)80007-7.Peer-Reviewed Original ResearchConceptsAdvanced diseaseHodgkin's diseaseModality approachSuch long-term complicationsIIIB Hodgkin's diseaseInduction chemotherapy regimensPrimary induction failureShort initial remissionAdvanced Hodgkin's diseaseDisease-free survivalOverall survival ratePrognosis of patientsLong-term complicationsInduction failureAggressive therapyChemotherapy regimensComplete remissionInitial remissionLate complicationsSecond malignanciesCombination chemotherapySurvival benefitMOPP regimenActual survivalCombined modalityProlonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Fisher R, DeVita V, Hubbard S, Simon R, Young R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals Of Internal Medicine 1979, 90: 761-3. PMID: 434676, DOI: 10.7326/0003-4819-90-5-761.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProlonged disease-free survivalDisease-free survivalLong-term survivalMOPP chemotherapyMOPP therapyComplete remissionMedian survivalMedian durationRe-treatmentMOPPRemissionHodgkinPatientsRelapseReinductionNitrogen mustardMonthsSurvivalDiseasePrednisoneDurationProcarbazineChemotherapyVincristine
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvival